Congress’ Next Steps On REMS Abuses: Will Improving FDA-FTC Communication Help?
Executive Summary
US FDA has seen little success in ending gaming of the patent process by brand name manufacturers. One problem: the agency’s referrals to FTC on anti-competitive cases appear go into a black box.